EHA 2017 | Is denosumab superior to zoledronic acid in the treatment of bone metastases in MM?
Evangelos Terpos, MD, PhD from the University of Athens, Athens, Greece, discusses the outcomes of a clinical trial (NCT00330759) evaluating the effectiveness of denosumab compared to zoledronic acid in the treatment of bone metastases in subjects with advanced cancer and multiple myeloma (MM). Here, he explains that the three major focus points, namely safety, progression-free survival and prolongation of skeletal events were better for denosumab than for zoledronic acid and notes that the results are promising, but require further investigation. This interview was filmed at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.
Get great new content delivered to your inboxSign up